VEA
CRBP icon

Virtus ETF Advisers’s Corbus Pharmaceuticals CRBP Stock Holding History

Virtus ETF Advisers’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,487
Closed -$80K – 359
2020
Q3 		$80K Sell
1,487
-203
-12% -$36.8K 0.04% 321
2020
Q2 		$425K Sell
1,690
-688
-29% -$139K 0.2% 177
2020
Q1 		$374K Sell
2,378
-347
-13% -$58.7K 0.15% 202
2019
Q4 		$446K Buy
2,725
+1,496
+122% +$221K 0.07% 222
2019
Q3 		$180K Sell
1,229
-69
-5% -$12K 0.04% 264
2019
Q2 		$270K Sell
1,298
-56
-4% -$12K 0.06% 260
2019
Q1 		$282K Sell
1,354
-184
-12% -$40.6K 0.6% 63
2018
Q4 		$269K Sell
1,538
-1,043
-40% -$208K 0.05% 149
2018
Q3 		$585K Sell
2,581
-1,849
-42% -$299K 0.06% 104
2018
Q2 		$671K Buy
4,430
+1,014
+30% +$184K 0.59% 114
2018
Q1 		$625K Buy
3,416
+1,835
+116% +$412K 0.54% 102
2017
Q4 		$337K Sell
1,581
-283
-15% -$60.6K 0.42% 107
2017
Q3 		$400K Buy
1,864
+171
+10% +$33.5K 0.05% 112
2017
Q2 		$320K Buy
1,693
+608
+56% +$119K 0.05% 108
2017
Q1 		$268K Buy
1,085
+104
+11% +$25.5K 0.05% 154
2016
Q4 		$249K Buy
+981
New +$225K 0.07% 144

Other funds holding CRBP

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtus ETF Advisers's CRBP Position: Q4 2020 in Review

Virtus ETF Advisers sold out of Corbus Pharmaceuticals (CRBP) in Q4 2020, closing a stake of 1,487 shares — an estimated $80K sold.

Virtus ETF Advisers first reported a position in CRBP in Q4 2016 and held it in 16 quarters. The position peaked at $671K in Q2 2018. 107 funds tracked by Wall St. Rank hold CRBP as of Q4 2020.

  • Virtus ETF Advisers reported no remaining Corbus Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Virtus ETF Advisers sold 1,487 Corbus Pharmaceuticals shares in Q4 2020, an estimated $80K.
  • Virtus ETF Advisers first reported a position in Corbus Pharmaceuticals in Q4 2016 and held it in 16 quarters.
  • Virtus ETF Advisers's Corbus Pharmaceuticals position peaked at $671K in Q2 2018.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2020.

Based on Virtus ETF Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.